Evidence map›Paper›PMID 29181514›Full record

ArticleAnnals of internal medicine2018

Comparative Analysis of Biopsy Upgrading in Four Prostate Cancer Active Surveillance Cohorts.

Lurdes Y T Inoue, Daniel W Lin, Lisa F Newcomb, Amy S Leonardson, Donna Ankerst, Roman Gulati, H Ballentine Carter, Bruce J Trock, Peter R Carroll, Matthew R Cooperberg and 5 more

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of internal medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 39 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Active surveillance for prostate cancer.Translational andrology and urology · 2021
    Review
  13. Article
  14. Article
  15. Article
  16. Observational
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 7 institutions in 3 countries.

Lurdes Y T InoueFrom University of Washington, Seattle, Washington; Fred Hutchinson Cancer Research Center, Seattle, Washington; Technical University of Munich, Garching, Germany; The James Buchanan Urological Institute, Johns Hopkins Medical Institutions, Baltimore, Maryland; University of California, San Francisco, San Francisco, California; University of Toronto, Toronto, Ontario, Canada; and Vanderbilt University, Nashville, Tennessee.
Daniel W LinFrom University of Washington, Seattle, Washington; Fred Hutchinson Cancer Research Center, Seattle, Washington; Technical University of Munich, Garching, Germany; The James Buchanan Urological Institute, Johns Hopkins Medical Institutions, Baltimore, Maryland; University of California, San Francisco, San Francisco, California; University of Toronto, Toronto, Ontario, Canada; and Vanderbilt University, Nashville, Tennessee.
Lisa F NewcombFrom University of Washington, Seattle, Washington; Fred Hutchinson Cancer Research Center, Seattle, Washington; Technical University of Munich, Garching, Germany; The James Buchanan Urological Institute, Johns Hopkins Medical Institutions, Baltimore, Maryland; University of California, San Francisco, San Francisco, California; University of Toronto, Toronto, Ontario, Canada; and Vanderbilt University, Nashville, Tennessee.
Amy S LeonardsonFrom University of Washington, Seattle, Washington; Fred Hutchinson Cancer Research Center, Seattle, Washington; Technical University of Munich, Garching, Germany; The James Buchanan Urological Institute, Johns Hopkins Medical Institutions, Baltimore, Maryland; University of California, San Francisco, San Francisco, California; University of Toronto, Toronto, Ontario, Canada; and Vanderbilt University, Nashville, Tennessee.
Donna AnkerstFrom University of Washington, Seattle, Washington; Fred Hutchinson Cancer Research Center, Seattle, Washington; Technical University of Munich, Garching, Germany; The James Buchanan Urological Institute, Johns Hopkins Medical Institutions, Baltimore, Maryland; University of California, San Francisco, San Francisco, California; University of Toronto, Toronto, Ontario, Canada; and Vanderbilt University, Nashville, Tennessee.
Roman GulatiFrom University of Washington, Seattle, Washington; Fred Hutchinson Cancer Research Center, Seattle, Washington; Technical University of Munich, Garching, Germany; The James Buchanan Urological Institute, Johns Hopkins Medical Institutions, Baltimore, Maryland; University of California, San Francisco, San Francisco, California; University of Toronto, Toronto, Ontario, Canada; and Vanderbilt University, Nashville, Tennessee.
H Ballentine CarterFrom University of Washington, Seattle, Washington; Fred Hutchinson Cancer Research Center, Seattle, Washington; Technical University of Munich, Garching, Germany; The James Buchanan Urological Institute, Johns Hopkins Medical Institutions, Baltimore, Maryland; University of California, San Francisco, San Francisco, California; University of Toronto, Toronto, Ontario, Canada; and Vanderbilt University, Nashville, Tennessee.
Bruce J TrockFrom University of Washington, Seattle, Washington; Fred Hutchinson Cancer Research Center, Seattle, Washington; Technical University of Munich, Garching, Germany; The James Buchanan Urological Institute, Johns Hopkins Medical Institutions, Baltimore, Maryland; University of California, San Francisco, San Francisco, California; University of Toronto, Toronto, Ontario, Canada; and Vanderbilt University, Nashville, Tennessee.
Peter R CarrollFrom University of Washington, Seattle, Washington; Fred Hutchinson Cancer Research Center, Seattle, Washington; Technical University of Munich, Garching, Germany; The James Buchanan Urological Institute, Johns Hopkins Medical Institutions, Baltimore, Maryland; University of California, San Francisco, San Francisco, California; University of Toronto, Toronto, Ontario, Canada; and Vanderbilt University, Nashville, Tennessee.
Matthew R CooperbergFrom University of Washington, Seattle, Washington; Fred Hutchinson Cancer Research Center, Seattle, Washington; Technical University of Munich, Garching, Germany; The James Buchanan Urological Institute, Johns Hopkins Medical Institutions, Baltimore, Maryland; University of California, San Francisco, San Francisco, California; University of Toronto, Toronto, Ontario, Canada; and Vanderbilt University, Nashville, Tennessee.
Janet E CowanFrom University of Washington, Seattle, Washington; Fred Hutchinson Cancer Research Center, Seattle, Washington; Technical University of Munich, Garching, Germany; The James Buchanan Urological Institute, Johns Hopkins Medical Institutions, Baltimore, Maryland; University of California, San Francisco, San Francisco, California; University of Toronto, Toronto, Ontario, Canada; and Vanderbilt University, Nashville, Tennessee.
Laurence H KlotzFrom University of Washington, Seattle, Washington; Fred Hutchinson Cancer Research Center, Seattle, Washington; Technical University of Munich, Garching, Germany; The James Buchanan Urological Institute, Johns Hopkins Medical Institutions, Baltimore, Maryland; University of California, San Francisco, San Francisco, California; University of Toronto, Toronto, Ontario, Canada; and Vanderbilt University, Nashville, Tennessee.
Alexandre MamedovFrom University of Washington, Seattle, Washington; Fred Hutchinson Cancer Research Center, Seattle, Washington; Technical University of Munich, Garching, Germany; The James Buchanan Urological Institute, Johns Hopkins Medical Institutions, Baltimore, Maryland; University of California, San Francisco, San Francisco, California; University of Toronto, Toronto, Ontario, Canada; and Vanderbilt University, Nashville, Tennessee.
David F PensonFrom University of Washington, Seattle, Washington; Fred Hutchinson Cancer Research Center, Seattle, Washington; Technical University of Munich, Garching, Germany; The James Buchanan Urological Institute, Johns Hopkins Medical Institutions, Baltimore, Maryland; University of California, San Francisco, San Francisco, California; University of Toronto, Toronto, Ontario, Canada; and Vanderbilt University, Nashville, Tennessee.
Ruth EtzioniFrom University of Washington, Seattle, Washington; Fred Hutchinson Cancer Research Center, Seattle, Washington; Technical University of Munich, Garching, Germany; The James Buchanan Urological Institute, Johns Hopkins Medical Institutions, Baltimore, Maryland; University of California, San Francisco, San Francisco, California; University of Toronto, Toronto, Ontario, Canada; and Vanderbilt University, Nashville, Tennessee.
Fred Hutch Cancer Center · USUniversity of California, San Francisco · USJohns Hopkins University · USUniversity of Toronto · CAUniversity of Washington Applied Physics Laboratory · USTechnical University of Munich · DEVanderbilt University · US

Funding

TRANSCRIPTOME AND PROTEOME STRATIFICATION OF PROSTATE ADENOCARCINOMA PHENOTYPESP50CA097186 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI John Kyung Lee · 2002 to 2026
$58.1M
Modeling to Improve Prostate Cancer Outcomes Across Diverse PopulationsU01CA199338 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI DE KONING, HARRY J, ETZIONI, RUTH D · 2015 to 2019
$5.2M
PROMISS - Prostate Modeling to Identify Surveillance StrategiesR01CA183570 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI ETZIONI, RUTH D, LIN, DANIEL W. · 2013 to 2017
$2.9M
Modeling Breast Cancer Recurrence Using New Statistical Methods for Semi-Markov PR01CA160239 · NCI · UNIVERSITY OF WASHINGTON · PI INOUE, LURDES Y.T. · 2011 to 2013
$937k
NCI NIH HHS P50 CA097186NCI NIH HHS R01 CA160239NCI NIH HHS R01 CA183570NCI NIH HHS U01 CA199338
6 · The paper itself

Abstract

Background: Active surveillance (AS) is increasingly accepted for managing low-risk prostate cancer, yet there is no consensus about implementation. This lack of consensus is due in part to uncertainty about risks for disease progression, which have not been systematically compared or integrated across AS studies with variable surveillance protocols and dropout to active treatment. Objective: To compare risks for upgrading from a Gleason score (GS) of 6 or less to 7 or more across AS studies after accounting for differences in surveillance intervals and competing treatments and to evaluate tradeoffs of more versus less frequent biopsies. Design: Joint statistical model of longitudinal prostate-specific antigen (PSA) levels and risks for biopsy upgrading. Setting: Johns Hopkins University (JHU); Canary Prostate Active Surveillance Study (PASS); University of California, San Francisco (UCSF); and University of Toronto (UT) AS studies. Patients: 2576 men aged 40 to 80 years with a GS between 2 and 6 and clinical stage T1 or T2 prostate cancer enrolled between 1995 and 2014. Measurements: PSA levels and biopsy GSs. Results: After variable surveillance intervals and competing treatments were accounted for, estimated risks for biopsy upgrading were similar in the PASS and UT studies but higher in UCSF and lower in JHU studies. All cohorts had a delay of 3 to 5 months in detecting upgrading with biennial biopsies starting after a first confirmatory biopsy versus annual biopsies. Limitation: The model does not account for possible misclassification of biopsy GS. Conclusion: Men in different AS studies have different risks for biopsy upgrading after variable surveillance protocols and competing treatments are accounted for. Despite these differences, the consequences of more versus less frequent biopsies seem to be similar across cohorts. Biennial biopsies seem to be an acceptable alternative to annual biopsies. Primary Funding Source: National Cancer Institute.

Indexed as

Watchful WaitingAdultAgedAged, 80 and overBiomarkers, TumorBiopsyDisease ProgressionHumansMaleMiddle AgedNeoplasm GradingProstate-Specific AntigenProstatic NeoplasmsRisk AssessmentRisk FactorsUnited StatesBiomarkers, TumorProstate-Specific Antigen

Identifiers

PMID29181514
PMCPMC5752581
OpenAlexW2770723187

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.